study_start,study_end,eligible_patients,treated_patients,treated_paxlovid,treated_sotrovimab,treated_remdesivir,treated_molnupiravir,treated_casirivimab,high_risk_cohort_2plus,high_risk_cohort_lower,high_risk_cohort_upper
2021-12-11,2022-04-28,102170,18210,4290,9340,20,4500,50,16300,1,6
